ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Hospital Universitario de Jaén
Jaén, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Jaén (9)
2019
-
Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study
Scientific Reports, Vol. 9, Núm. 1
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
2014
-
Consenso sobre la biopsia selectiva del ganglio centinela en el cáncer de mama. Revisión 2013 de la Sociedad Española de Senología y Patología Mamaria
Revista Espanola de Patologia
-
Consensus on sentinel lymph node biopsy in breast cancer. Review of the Spanish Society of Senology and Breast Pathology 2013
Revista de Senologia y Patologia Mamaria, Vol. 27, Núm. 1, pp. 43-53
2013
-
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Núm. 3, pp. 381-391
-
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
Journal of Clinical Oncology
2011
-
Hormone-responsive breast cancer
Advances in Therapy, Vol. 28, Núm. 12, pp. 1045-1058
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
2007
-
Current controversies in the management of early breast cancer
Clinical and Translational Oncology, Vol. 9, Núm. 6, pp. 375-384